The Drug Discovery Services Market includes a broad range of outsourced research activities that help pharmaceutical and biotechnology companies progress from biological targets to potential drug candidates. The market is segmented by process phase, technology, drug type, therapeutic area, end user, and region.

Hit generation and screening represented 38.5% of market revenue in 2025, making it the largest process-phase segment. Automated screening, combinatorial libraries, and DNA-encoded library technologies are supporting higher research throughput. Preclinical candidate selection is projected to grow at a 7.55% CAGR as sponsors increasingly seek translational and IND-ready data from external providers.

High-throughput screening represented 36.7% of revenue in 2025, while bioinformatics generated significant demand through sequence analysis, target discovery, and pathway research. AI and machine learning are expected to be the fastest-growing technology segment, supported by generative molecular design and virtual screening.

Small molecules accounted for 57.3% of revenue in 2025, although biologics and large molecules are expanding rapidly. Oncology was the leading therapeutic area, representing 29.7% of revenue. Pharmaceutical and biotechnology companies remained the largest end-user group, accounting for 60.4% of market revenue.

The future of the industry will increasingly depend on integrated platforms combining laboratory automation, computational biology, AI, screening, medicinal chemistry, and preclinical research. These capabilities can help sponsors reduce development timelines while accessing specialized expertise.